↓ Skip to main content

Dove Medical Press

Article Metrics

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects

Overview of attention for article published in OncoTargets and therapy, April 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
19 Mendeley
Title
Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects
Published in
OncoTargets and therapy, April 2012
DOI 10.2147/ott.s23874
Pubmed ID
Authors

Akinori Sato

Abstract

Histone acetylation and deacetylation play important roles in the regulation of gene transcription and in the modulation of chromatin structure. The levels of histone acetylation are determined by the activities of histone acetyltransferases and histone deacetylases (HDACs). HDACs are associated with a number of oncogenes and tumor suppressor genes and can be aberrantly expressed and/or inappropriately activated in cancer cells. HDAC inhibitors have therefore recently emerged as a novel treatment modality against malignancies. They regulate gene expression by enhancing the acetylation of not only histones but also nonhistone proteins, including transcription factors, transcription regulators, signal transduction mediators, and DNA repair enzymes, and they inhibit cancer growth. Vorinostat (suberoylanilide hydroxamic acid) is one of the most potent HDAC inhibitors, and was approved in Japan in 2011 for the treatment of cutaneous T-cell lymphoma. Numerous clinical trials have shown it to be effective against cutaneous T-cell lymphoma but less so against other types of cancer. Because vorinostat can overcome resistance to or enhance the efficacy of other anticancer agents, such as 5-fluorouracil, carboplatin, paclitaxel, bortezomib, and tamoxifen, combination therapies using vorinostat and these agents have been investigated. This review introduces the background and mechanism of action of vorinostat and describes the results of clinical trials using vorinostat, both as a single agent and in combination with other anticancer agents, against cutaneous T-cell lymphoma and other malignancies.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Canada 1 5%
Unknown 18 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 21%
Researcher 3 16%
Student > Bachelor 3 16%
Other 2 11%
Student > Doctoral Student 1 5%
Other 4 21%
Unknown 2 11%
Readers by discipline Count As %
Medicine and Dentistry 4 21%
Agricultural and Biological Sciences 4 21%
Biochemistry, Genetics and Molecular Biology 3 16%
Chemistry 2 11%
Computer Science 1 5%
Other 3 16%
Unknown 2 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2012.
All research outputs
#7,200,501
of 12,475,053 outputs
Outputs from OncoTargets and therapy
#352
of 1,548 outputs
Outputs of similar age
#58,555
of 119,230 outputs
Outputs of similar age from OncoTargets and therapy
#4
of 12 outputs
Altmetric has tracked 12,475,053 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,548 research outputs from this source. They receive a mean Attention Score of 2.4. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 119,230 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.